New research published in the Equine Veterinary Journal (EVJ) has shown that the use of standing sedation to repair lower limb fractures in racehorses produces similar results to surgery performed under a general anaesthetic, but with the advantages of less surgical complexity, time, cost and risk.
The study Short and long term results following standing fracture repair in 34 horses was conducted by Richard Payne and Polly Compston at Rossdales Equine Hospital1.
Standing fracture repair in the horse is a relatively new surgical procedure with very little follow-up data available. Treatable fractures sustained by racehorses in the UK have traditionally been repaired under general anaesthesia but it is well known that this carries an increased risk of anaesthetic-related death compared with other elective surgical procedures. However, despite the substantial increase in the number and type of surgical procedures performed under standing sedation over the past decade there has previously been very little work undertaken on standing fracture repairs.
The study looked at the case records of 34 Thoroughbred and Arab racehorses that had a lower limb fracture surgically repaired by one surgeon at Rossdales up until June 2011. The injuries included non-displaced fractures of the proximal phalanx, the third metacarpal bone and the third metatarsal bone, all of which are relatively common fracture sites in racehorses. Hospital records, owner and trainer telephone questionnaires and website research were used to evaluate follow-up. The short and long-term results were similar to those of horses undergoing repair of comparable fracture configurations under general anaesthesia, with 20 of the horses returning to racing within an average of 226 days.
This early research indicates potential for tangible benefits, including avoidance of the inherent risks of general anaesthesia as well as a reduction in surgical complexity and associated costs, leading the way for future research into larger cohorts of horses.
EVJ's Editor Celia Marr said: "The recent fatalities at the Grand National highlight that it is critical that the equine veterinary research community strives to reduce the prevalence of fractures in our racehorses. We also need to continue to seek better ways of treating those horses that do develop fractures and, while not every fracture will be amenable to this approach, this study is an important first step towards treating some of the non-displaced fractures that occur in racehorses without the need for anaesthesia."
1Short and long term results following standing fracture repair in 34 horses Richard Payne and Polly Compston, Equine Veterinary Journal ISSN 0425-1644 DOI: 10.1111/j.2042-3306.2012.00569.x
Virbac has launched Inflacam, a meloxicam-based NSAID for the alleviation of pain in both acute and chronic musculo-skeletal disorders in dogs and horses.
Inflacam is presented both as an oral suspension and as a chewable tablet for dogs. The suspension is available in 200ml, 100ml, 42ml and 15ml sizes with a measuring syringe provided. The tablets come in two sizes - 1 mg and 2.5 mg - and are available in packs of 100. It is available for horses as an oral suspension.
Virbac Product Manager Chris Geddes MRCVS, said: "Virbac is well known for launching innovative products in areas such as dermatology and reproduction but we also aim to support practices by offering tried and trusted practice 'standards' for everyday use. Inflacam fits this brief well - meloxicam is the most commonly-used NSAID in dogs and we are delighted to add it to our range."
For more information contact your territory manager or call Virbac on 01359 243 243.
Carried out by the Royal Veterinary College (RVC), the Animal Health Trust (AHT) and Rossdales Equine Hospital, the study also revealed that the groups particularly at risk were native pony breeds and their crosses, as well as horses and ponies with a history of laminitis and those with lameness or soreness after routine hoof care.
This research, funded by World Horse Welfare, comes from the first ever online study that collected information on laminitis from a group of owners in real time.
The researchers say that the study is also the second largest to identify weight gain as a risk factor for laminitis. Data was collected from the owners of 1,070 horses and ponies in Great Britain, who reported their animal’s management, health and estimated weight via online questionnaires for 29 months.
Owners were encouraged to use a custom weight tracking tool designed by the study/research team to help regularly track changes in their animal’s weight and body condition. The uptake of this tool was high, with over half of participating owners using it.
The tool is freely available at: www.aht.org.uk/research/lameness/laminitis.
Other study findings included:
A high risk of laminitis was present in horses shod or trimmed at intervals of more than 8 weeks, and in those that took a long time to return to soundness after a bout of laminitis.
Diet, grazing management and health were factors closely associated with the development of laminitis and will be the subject of future investigation.
Researchers also noted that weight gain often occurred unintentionally, even when owners were aiming for their animals to maintain or lose it. This reiterates the need to consistently record weight and body condition in order to prevent undesirable weight gain.
Dr. Dee Pollard of the AHT, one of the study’s chief authors, said: "This is one of the largest, and the first, online laminitis studies where we collected regular information from the same group of owners in real-time. We assessed the relationship between laminitis and many potential management and health factors and identified those more likely to be present before a laminitis episode was reported.
"We now have good evidence to develop laminitis prevention guidelines, and a number of different avenues to explore in the future. We cannot emphasise enough how important systematic and regular weight and body condition monitoring are. It’s very easy to miss weight gain when you are just relying on your eyes and you see your horse or pony every day. You need to get hands on, feel for the fat deposits and take measurements, remember the figures don’t lie!"
Reference
The Fédération Équestre Internationale (FEI) has added Metacam for Horses to its 'list of detection times'.
According to the manufacturer, Boehringher Ingelheim Vetmedica, Metacam (meloxicam) is the first preferential COX-2 inhibitor to be added to this list, and has stated plasma and urine detection times of 72 hours administered intravenously or orally1. This is the shortest urine detection time of the NSAIDs available for use in horses, and compares to the 168-hour (7 days) detection time for phenylbutazone stated by the FEI.
Craig Beck, equine sales and marketing manager for Boehringer Ingelheim in the UK and Ireland said: "We have been very happy to work in partnership with the FEI to provide the robust data that has supported the FEI in their analysis of Metacam. Metacam is an important addition to the FEI list, that will help vets treating competition horses. There is now a modern and proven NSAID which extends the therapeutic options available to vets."
Metacam is licensed in horses for the alleviation of inflammation and relief of pain associated with musculo-skeletal disorders or colic.
For further information, please contact your Boehringer Ingelheim Vetmedica territory manager or call 01344 746959.
1 Detection Time agreed with the European Horse Racing Scientific Liaison Committee (EHSLC)
The successful candidates, who completed their studies during 2020 and passed the examination in November, are Lucy Wilson (pictured right), from Equibreed UK, Reading, Vanessa Austin, who works at at Vets4Pets, Northampton, and Donna Johnson, the Clinical Services Manager at The Pet Vet, Barnsley.
Lucy said: “I chose to do the CVPM to cement my knowledge of how to run our practice to the best of my ability and to provide the highest level of support to my colleagues. The CVPM resources, syllabus and experience have given me a thorough understanding of my skills and areas to develop. I cannot recommend the experience highly enough.”
Chair of the VMG Certification and Training Committee, Philippa Davies, said: “The CVPM exam tests candidates’ skills in operational management, prioritising, strategy, and thinking on your feet. It’s a gruelling assessment and holders are an elite group. We are delighted to welcome Vanessa, Donna and Lucy and congratulate them on their achievement.”
For more information, visit: https://www.vetmg.com/education/cvpm/
The webinar will take place at 11am and will be repeated at 7.30pm for those who are unable to listen during the day.
Hosted by Zoetis vet Dr Wendy Talbot the session will last for approximately an hour and equates to 8 AMTRA CPD points.
Wendy will explain the current situation and recommended approaches to help slow resistance.
The webinar will conclude with a live Q&A to give everyone the opportunity to discuss any queries, concerns or common questions they hear from their customers with Wendy.
Zoetis Equine Product Manager, Penny McCann said: "Our webinars continue to be very well received.
“This one is particularly important as it explains the important new thinking around the use of anthelmintics in order to address the serious challenge of resistance.
"It’s a must for all those involved with prescribing.”
To book the 11am webinar: https://register.gotowebinar.com/register/6163460189961597967 To book the 7.30pm webinar: https://register.gotowebinar.com/register/6394015684169009164
Vetoquinol has launched Myo Power, the latest addition to the Equistro Performance range of nutritional supplements.
The company says that Myo Power has been formulated with the performance and convalescent horse in mind, and that it is an excellent source of easily digestible protein enriched with L-Leucine and other key essential amino acids necessary for optimal muscular cell development, specifically via the mitochondria.
Vetoquinol claims the product is extremely beneficial for young horses being prepared for sales, competition horses in training, and the convalescent or older horse following periods of box rest or restricted exercise.
Myo Power is available in 1.2kg and 2.3kg tubs. For further information, please contact your local Vétoquinol Territory Manager.
The app gives users the ability to find information on over 1000 animal medicine listings included on the compendium website; with the complete datasheets available for viewing.
The new app also allows you to scan datamatrix barcodes on veterinary medicinal product packaging to take you straight to important product information. You can also search by medication, manufacturer or GTIN.
Dawn Howard, NOAH’s Chief Executive said: "The NOAH Compendium is the recognised industry reference, and it is essential we fully utilise the information offered in the compendium with modern technology, whilst protecting the integrity and respect that it holds.
"The website, which we relaunched earlier this year, has had over 8.5 million views to date. We feel this app serves as a great addition to this modern method of accessing data – meaning users are no longer reliant on internet access to obtain the information they need.
"As an organisation, we will continue to embrace new technologies to ensure animal medicine is used correctly and responsibly in the UK. The launch of this new app goes towards ensuring all those who prescribe or use animal medicines have access to the latest technical information available for companion and farm animals when they need it."
Pat is the head of the Equine Studies Group at Waltham Petcare Science Institute and an internationally renowned authority on equine nutrition from both veterinary and academic perspective.
Her courses, book publications and webinars are aimed at providing practising equine vets with the latest knowledge and essential know-how on equine nutrition, whether for performance horses, leisure animals or the retired family pony.
Earlier this month Pat was one of several speakers at the British Equine Veterinary Association’s CPD course: From superfoods to supplements: How to know more than the owner.
Earlier this year she co-edited and co-authored two chapters of Veterinary Clinics Equine Practice: Nutrition: 1) What would be good for all veterinarians to know about equine nutrition, and 2) Nutritional considerations when dealing with an obese adult equine.
Next month she will chair a panel discussion titled Nutritional Management of the Competitive Equine Athlete for Vets through VetPD.
In the autumn she will be one of several speakers at the Mars Equestrian Equine Veterinary Continuing Education Series focusing on senior, obese and laminitic horses.
For more information, visit: www.spillers-feeds.com
New research from the USA, published in the Equine Veterinary Journal (EVJ), has shown that a toxin from the box elder tree is the likely cause of Seasonal Pasture Myopathy (SPM), the US equivalent of the European disease known as Atypical Myopathy (AM).
According to the British Equine Veterinary Association, preliminary comparisons of these results with cases of AM in Europe suggest that the European condition may be linked to similar trees which could have an important bearing on the future prevention of the disease in Europe.
Seasonal Pasture Myopathy is a highly fatal muscle disease in Midwestern USA and Eastern Canada. A similar disorder called Atypical Myopathy is becoming increasingly frequent in the UK and Northern Europe. Outbreaks of both diseases tend to be seasonal, with most cases occurring in the autumn. Horses that develop SPM and AM are usually kept in sparse pastures with an accumulation of dead leaves dead wood and trees in or around the pasture and are often not fed any supplementary hay or feed.
The research1 identified that seeds from box elder trees were consistently present in the autumn pastures of all 12 horses enrolled in the study. These horses were from 11 different farms and had all presented with the clinical signs of SPM, which include muscular weakness and stiffness, dark urine, periods of recumbency, colic-like signs and muscle trembling. The toxic amino acid hypoglycin A, which is known to cause acquired multiple acyl CoA dehydrogenase deficiency (MADD) was shown to be present in the box elder seeds and hypoglycin metabolites were identified in the serum or urine of all the horses. All but one of the cases proved fatal.
Professor Valberg DVM PhD of the Department of Veterinary Population Medicine, College of Veterinary Medicine, University of Minnesota, who instigated the study, said: "The fact that another acquired form of MADD in rats and humans is caused by hypoglycin A ingestion strengthens our conclusion that hypoglycin A is the likely toxic cause of SPM in horses. We are intending to conduct further studies to determine the factors that affect the highly variable hypoglycin A concentrations in box elder seeds."
Professor Valberg has established collaborative links with groups in Europe in order to investigate if a similar toxin is involved in European Atypical Myopathy. Working with Professor Vince Gerber and Dr Lucia Unger at the University of Bern, Professor Valberg has obtained seeds from a tree related to the Box Elder found on many pastures where Atypical Myopathy has occurred.
Professor Celia Marr, Editor of Equine Veterinary Journal said: "This is a really important step forwards. We don't yet know for sure that the cause of European disease, Atypical Myopathy, is the same as Seasonal Pasture Myopathy in the US. But the clinical signs and MADD aberrations are identical and both conditions have a high fatality rate. It remains to be seen whether this research will help European horses, but there is no doubt that it will allow American horse owners to prevent this devastating condition affecting their horses with immediate effect."
1 Seasonal Pasture Myopathy/Atypical Myopathy in North America associated with Ingestion of Hypoglycin A within Seeds of the Box Elder Tree Stephanie J Valberg DVM PhD1, Beatrice T Sponseller Dr. med. vet2, Adrian D Hegeman PhD3, Jennifer Earing PhD, Jeffery B. Bender DVM MS1, Krishona L Martinson PhD4, Steven E Patterson PhD5, Lawrence Sweetman PhD1
Boehringer Ingelheim Vetmedica has launched a series of information sheets written by veterinary surgeons, nutritionists and leading riders to support its muscle building supplement for horses, Equitop Myoplast Power Pearls.
Available to download as PDFs from its website - http://www.equitop-myoplast.co.uk - this resource for horse owners covers a range of feeding topics including training the young showjumper and feeding the performance horse, older horses and horses during periods of rest and recuperation.
New video and written testimonials from performance riders and veterinary surgeons are now on the website, which also offers owners advice on healthy lean muscle growth and the benefits of Equitop Myoplast. Olympic dressage rider, Emile Faurie, international showjumpers, Ellen Whitaker and Scott Brash, and show horse producer, Katie Jerram, all endorse the product.
A client leaflet has also been launched featuring the testimonials and providing owners with information on Equitop Myoplast and an online offer of £15 off their first purchase of the supplement by downloading a voucher from the website.
Boehringer says Equitop Myoplast is packed with 18 key amino acids and is scientifically designed to support lean muscle growth, not bulk. The company says the supplement is great for optimising performance in horses in intensive training and competition, as well as bringing on young, breeding and injured animals, and for older horses which lose condition easily.
Boehringer Ingelheim VetMedica has published its equine endocrine webinars online for veterinary professionals to view on demand at www.prascend.co.uk/webinars.
The webinars, which cover 'Diagnostic challenges in equine endocrine disease', presented by equine internal medicine specialist Andy Durham from the Liphook Equine Hospital, and 'A problem-based approach to equine laminitis', presented by equine internal medicine specialist Dr Catherine McGowan from the University of Liverpool, are each one hour long.
Participants will each receive CPD certificates for participation.
The Arthrex Vet Systems Mobile Lab will be hosting hands-on sessions to help practitioners develop their arthroscopy and joint block skills in its state-of-the-art laboratory.
BEVA President Roger Smith said: “Our practical sessions are always highly popular and the wetlab experience takes things to the next level."
"The ability to practice ultrasound-guided injections at the conference provides the opportunity to hone your skills in ultrasound and enable you to cement to ultrasound-guided injections of tendons and ligaments and joints into your daily practice.
On the Thursday there will be three wetlab taster sessions at three different stations, giving delegates the chance to sharpen their skills with an ultrasound scanner, arthroscope and arthrobox.
Friday’s sessions will be focused on forelimb joint blocks and arthroscopic demonstrations of the needle locations.
The full BEVA Congress programme is now live and super early bird tickets are available until 7th June 2024.
Individual super early bird BEVA members prices are £524 for vets and £144 for vet nurses for all three days (with concessionary available for those in their first three years of graduation or earning less than £25,000).
Day tickets and practice passes are also available.
http://www.bevacongress.org
A new study published in Equine Veterinary Journal's (EVJ) in partnership with the American Association of Equine Practitioners, has shown that a wireless, inertial sensor-based system can effectively measure a horse's response to a flexion test.
The authors say that opinions on the value of flexion tests in assessing equine lameness have been divided for many years, but their research should turn what has always been regarded as a subjective process into a wholly objective one.
Flexion tests are used routinely in horses with subtle or imperceptible lameness, to exacerbate the problem and make it apparent to the observer. The test involves applying a short period of pressure to the joints of the limb before re-examination, and evaluating any change in gait. However, flexion tests rely on the ability of the observer to identify and interpret changes in the horse's gait and in that respect these tests are subjective and not necessarily consistent between observers.
The research study was conducted by orthopaedic surgeons based at the University of Glasgow's School of Veterinary Medicine1. A total of 17 healthy adult horses, all in work, were fitted with sensors before being trotted in a straight line. The sensors measured vertical pelvic movement asymmetry for both right and left hind limb strides and the average difference in maximum and minimum pelvic height between right and left hind limb strides. A hind limb was randomly selected for 60 seconds of proximal flexion, after which the horse was trotted for a minimum of 10 strides. Response to the flexion was blindly assessed as negative or positive by an experienced observer.
John Marshall, lecturer in equine surgery at the University of Glasgow, who led the study, said: "A positive response to flexion resulted in significant changes to objective measurements of pelvic symmetry, supporting the use of inertial sensor systems to objectively assess response to flexion tests."
Professor Jim Moore, North American Editor of the EVJ, said: "The introduction of an objective approach to documenting lameness examination will not only help vets and trainers to investigate equine lameness more accurately. It will also serve as an unbiased method of communicating lameness examination findings among vets, trainers, farriers and other professionals."
The next phase of research will be to establish cut-off values for objective assessment of other equine lameness diagnostic procedures, such as nerve blocks.
The British Equine Veterinary Association (BEVA) has announced that it is reducing the cost of its CPD by 50% this year and making its webinars free to members.
David Mountford, Chief Executive of BEVA said: "Last year we were able to capitalise on some efficiencies in other areas of BEVA operations. We are delighted to be able to hand the resulting benefits directly back to our members across all our CPD programme during 2013."
The Association says its CPD covers a broad range of topics is aimed at busy vets who need to build CPD points, whether new graduates, equine or mixed practitioners. It takes the form of clinical workshops, regional meetings, nursing meetings, webinars and one, two and three day practical courses, held in the UK.
This year's courses include:
For more information, visit http://www.beva.org.uk/news-and-events/beva-courses or ring +44(0)1638 723555 or email info@beva.org.uk.
BVA President Gudrun Ravetz said: "Veterinary View not only highlights some of the veterinary profession's fantastic work, but complements our joint project with RCVS, Vet Futures, in exploring how the profession can best shape its own future. We hope it will stimulate debate among vets, and the wider community in which we work, about both the big challenges and opportunities that the veterinary profession is facing."
The series includes a number of videos which showcase more recent industry developments:
Stem Cell therapy for the treatment of canine osteoarthritis (VetCell Therapeutics)
Pharmtrax, a mobile device for vets to record work and dispensing on the farm (Henry Schein Animal Health)
Hormone implants as an alternative to castration (Virbac Animal Health)
Practice management support from Zoetis
Preventing an epidemic of equine flu (Merial Animal Health)
MSD Animal Health has announced the launch of KBHH Yard Master – a new preventative healthcare and biosecurity app - as part of its ongoing Keeping Britain’s Horses Healthy (KBHH) campaign.
MSD says KBHH Yard Master has been created to link vets and yards where the majority of horses in Britain are kept. It aims to play a key role in protecting the health and welfare of the herd and in safeguarding the yard’s reputation and business.
Peter Young, Equine Business Manager at MSD Animal Health said: "Good biosecurity is essential in building and maintaining the reputation of a yard which, in turn, impacts on owner satisfaction and retention. It remains, however, a poorly understood subject despite its importance. We’ve therefore invested in the creation of KBHH Yard Master to help vets, yard managers, their employees and horse owners focus on preventative health and biosecurity measures; making best practice seem more achievable and easier to implement.
He added: "We were also fortunate to have input from Professor Josh Slater, who has been heavily involved in developing the content, evaluation and grading system behind the app assessment."
KBHH Yard Master covers all aspects of biosecurity, including everyday husbandry practices, managing new arrivals, running isolation facilities, infection control and personnel movement. MSD says it will frame a dialogue with yard managers regarding preventative healthcare and biosecurity in situ and provide instant feedback on current practices and risk. Following the on-site assessment, a report can be sent to the yard manager with tailor-made recommendations and timings, detailing how they can improve their yard’s biosecurity performance.
Peter added: "Based on the data gathered through the KBHH campaign we know that approximately half of horses are vaccinated for ‘flu. This means that there will be horses on yards, visited by vets, that are not vaccinated. KBHH Yard Master will help identify those horses and allow the vet to recommend appropriate vaccination schedules."
MSD has produced a range of supporting KBHH Yard Master materials to promote understanding, participation and compliance amongst yard staff and owners, including posters and downloadable booklets which explain aspects such as disease prevention, infection control and outbreak control.
A certificate of excellence is also available to be awarded to those yards which, following assessment, have a low overall biosecurity risk.
For more information, contact your MSD Animal Health Equine Account Manager or call MSD on 01908 685685.
Intervet/Schering-Plough Animal Health has reported that since launch, its diagnostic service RespCheck has identified infectious diseases in 15 per cent of all animals checked under the scheme.
Offered to qualifying practices for no charge and implemented by the Animal Health Trust (AHT), Intervet/Schering Plough set up RespCheck to help identify the cause of infectious respiratory problems in horses.
The RespCheck kit, which has been used to swab more than 700 horses since launch, consists of naso pharyngeal swabs, enabling two horses per yard or outbreak to be swabbed for a variety of diseases. These include equine influenza, equine herpesvirus, Streptococcus equi (strangles), pasteurella, rhinovirus and Streptococcus zooepidemicus. The swabs are sent to the AHT for analysis and the results returned direct to the vet.
John Dickerson from Chine House Equine Hospital in Leicestershire said: "The service is fantastic, made all the better by being completely free of charge! The benefits are two-fold. From the clinical perspective it means we can discount or treat potential infections in a more timely fashion; for instance, we use RespCheck to screen for any suspected infectious respiratory disease cases which enables us to deal with the problem, through quarantine and strict hygiene measures, helping to prevent the spread of the disease.
The other benefit is to our practice reputation and the standard of service we can offer. It's great to be able to provide owners with peace of mind without it costing more than our call out fee. By the time an owner calls the vet they are usually stressed and worried about their horses symptoms and need some reassurance, which is exactly what RespCheck gives them. We are confident that providing a diagnostic service that is completely free and that puts an owners mind at rest regarding the risk of an infection can only be a good thing for our practice reputation and customer care.
Last year, the service proved its worth when the screening of a recently imported horse showed the animal had equine influenza. I believe that had RespCheck not been employed, we would have had an outbreak in that particular yard."
Practices interested in knowing more about RespCheck should contact their local Intervet/Schering-Plough Veterinary Business Manager or phone the company's Veterinary Support Group on 01908 685685.
BlueSky says that conventional treatment for equine sarcoids, which are induced by tumour antigens E6 and E7 of the bovine papillomavirus, have only limited effect and typically result in the recurrence of the tumours.
However, research published by the company in PLoSONE1 showed that sarcoids treated with delNS/E6E7 were completely and permanently eliminated.
For the study, 29 horses were treated with different regimes involving direct injection into the tumours over three years.
Visible and very significant regression of the sarcoids was achieved in 20 of the treated horses, and 100% regression of the sarcoids in 10 equine patients.
Thomas Muster, CEO of BlueSky Immunotherapies said: "The complete elimination of very aggressive and difficult-to-cure equine sarcoids is yet another important proof of the potential offered by our delNS platform."
In addition, the systemic delNS-mediated immune stimulation eliminated non-injected sarcoids and the papillomavirus that caused the sarcoids.
Thomas added: "We are therefore confident that we will also be able to successfully heal and/or eliminate the cervical tumours of the women enrolled in the clinical trials currently under way."
The College says this will pave the way for new diagnostic tests for what could be one of the most common causes of pregnancy loss in mares.
The researchers, led by Dr Mandi de Mestre (pictured right), Reader in Reproductive Immunology and Head of the Equine Pregnancy Laboratory at the RVC, collaborated with seven different veterinary practices to gain access to samples from across the UK and Ireland and found that around 20% of the pregnancies lost were aneuploid, which is when a copy of a whole chromosome is either duplicated or lost (similar to Down's).
Charlotte Shilton, RVC PhD, the student who performed the analysis, applied three different genetic approaches to confirm the results.
Work is now underway to identify the underlying cause of these aneuploid pregnancies, with early data from this study suggesting it is most commonly introduced via the egg or sperm. Until now, chromosomal defects such as aneuploidy have only been reported as a rare condition in young horses with developmental disorders.
The researchers say the study explains why the condition is so rare in horses, with most embryos and foetuses possessing this genetic change dying very early in development, as is also observed in human pregnancy. The study highlights the need to reconsider this genetic condition both in pregnancy loss but also for early developmental disorders.
Dr Mandi de Mestre, Reader in Reproductive Immunology at the RVC, said: “Early pregnancy loss remains a very frustrating condition for clinicians to treat as the underlying cause is unknown in around 80% of cases. These findings will allow researchers to develop new diagnostic tests for pregnancy losses, which would offer hope to thousands of owners of breeding mares that suffer this condition.
“A diagnostic test would allow them to make informed decisions on treatment strategies and to advise on whether they should invest in further attempts to breed their mare benefiting both horses and their breeders alike in the future. I would like to thank both the Thoroughbred Breeders Association and our collaborators at Texas A&M University and the participating veterinary surgeons for their support on this project.
The National Office of Animal Health has completed its annual review of its Code of Practice for the Promotion of Animal Medicines, and a number of changes will come into effect on 1st July 2011.
One change spells out the way antimicrobial medicines are promoted to farmers, with a firm emphasis on correct use and education.
Advertisers will be required to describe the condition the product is aiming to treat, and to promote an understanding of the treatment of the disease.
The phrase "use medicines responsibly" will always be included in text, making the voluntary strapline introduced in 2009 a formal part of the NOAH Code. As with all promotions to people other than prescribers, farmers will always be reminded to consult their veterinary surgeon.
Advertising text will always state clearly the name of the company and the brand being promoted, and promotion must not be designed to disguise its real nature.
Withdrawal periods for products will be stated, but these must not be unduly prominent and not in a font size greater than the body copy containing recommended dosage and species description.
The changes were proposed by NOAH within its formal response to the Veterinary Medicines Directorate's consultation on the Veterinary Medicines Regulation 2010. The Minister decided in December 2010 to continue to allow the advertising of antimicrobial veterinary products to farmers.
Phil Sketchley, NOAH Chief Executive, said: "Whilst welcoming the Government's decision in December not to further restrict the advertising of animal medicines, we feel that the industry should take a proactive role to ensure the system works properly. We believe it is important for farmers, who are legally responsible for the health and welfare of their animals and the food produced from them, to be aware of the medicines that are available to protect the health of their animals, and at the same time we want them to know that these medicines must be prescribed and used responsibly.
"The issue of antimicrobial resistance is one that affects us all. The way to promote best practice is through education by maintaining all lines of communication between farmers, vets, scientists and animal medicine producers.
"Antibiotics are essential for maintaining the health and welfare of all animals, but like any medicine they need to be used responsibly in order to maintain their effectiveness, and their availability for future generations."
Zoetis, formerly Pfizer Animal Health, has launched Flexi4, a nutritional supplement for horses containing a patented combination of natural plant extracts designed to help maintain joint flexibility and the management of joint pain.
Flexi4 contains a blend of four plant extracts, Curcumin, Yucca schidigera, Salix alba and Boswellia serrata, which the company says have been shown to have anti-inflammatory, anti-pyretic and analgesic properties as follows:
Mary King, Olympic three day eventing team silver medallist, said: "When performing at the highest level it's important that my horses' joints remain flexible and free of pain. Using Flexi4 has made them more resilient to aches and pains during intense training and I am confident when competing that my horses are feeling the benefit of this natural product, helping them to perform at their very best."
Flexi4 is an apple-flavoured gel that is fed as a once daily supplement. It doesn't contain any substances listed as prohibited by the FEI.* For more information, contact your Zoetis Account Manager, call 0845 300 8034 or email customersupportuk@zoetis.com.
References
*FEI prohibited substance list, 2013
The Veterinary Marketing Association has announced details of a new award for public relations, open to veterinary practices and companies.
The VMA says this award is to recognise the value that media and public relations can add to the marketing mix. It will be awarded to the company or veterinary practice that has delivered the most innovative PR campaign during 2011, as judged by a panel of industry professionals.
Organiser Claire Edmunds said: "The VMA Awards has become a coveted event for those involved in the animal health industry to showcase their marketing achievements. A range of categories has evolved since the awards began over 20 years ago, for marketing, creative communication and new media campaigns. However, we felt that an award for PR was required to complete the marketing mix".
Jane Manning from award sponsor Splash Marketing & Communications said: "We felt it was time to give the opportunity for those involved in PR to obtain the recognition they deserve alongside their creative colleagues.
"An effective PR campaign can be a highly influential marketing tool, so it's great news that the VMA has added this new award category. We hope that companies and agencies serving the animal health sector will embrace this new opportunity to showcase their creativity and hard work".
The award is for the most innovative PR initiative published during the year. This can be a single 'one-off' event or article, or a sustained campaign over a given period. The winner and two highly commended entries will be awarded at the VMA Awards on Friday 9th March 2012 at Shakespeare's UnderGlobe Theatre, London.
Further information on the awards and ticket application forms are available at the VMA's website - http://www.vma.org.uk/ or by calling 0844 561 6157. The deadline for entries is Friday 27th January 2012.
VetCell Bioscience has become the first UK-based stem cell centre to be authorised under the Veterinary Medicines Regulations.
Following a rigorous series of inspections and reports by Good Manufacturing Practice (GMP) Inspectors VetCell, in conjunction with their UK laboratory partner Biobest, were officially authorised as an equine stem cell centre on 1 October 2009.
David Mountford, Chief Operating Officer of VetCell Bioscience said: "To have received formal authorisation so swiftly reflects the high standard of our operation and our ability to lead the field in the increasingly competitive sector of stem cell technology."
Stem cell therapy involves implanting millions of the animal's own stem cells and autologous growth factors directly into the injured tendon or ligament. The service VetCell Bioscience offers is the collection, storage, processing and supply of stem cells suitable for administration back into the donor animal.
According to the company, there is considerable interest from the human sector and studies in human medicine, for the treatment of Achilles tendinopathies, could begin as early as next year.
The recommendation follows the analysis of data collected as part of the company's Talk About Laminitis disease awareness initiative, which has seen more than 47,000 horses tested for PPID since it was launched in 20121.
The data revealed that, regardless of presenting clinical signs, a horse aged 15-20 is three times more likely to have PPID compared to a horse under 10, and this risk increases with age. For example, a horse of 20-25 is six times more likely to have PPID compared to a horse under 10 and a horse that is 25-30 is 10 times more likely to have PPID.
Boehringer says that despite the high prevalence of PPID in the older horse population, the clinical signs of the disease are insidious in onset and owners may simply associate them with the ageing process.
One study demonstrated that in a single population of horses over the age of 15 only 1.6% of owners reported signs of PPID2. However, when the same group of horses were examined by a veterinary surgeon, 21% were found to have signs of the disease.
Dr Jo Ireland, veterinary surgeon at the University of Liverpool, said: "It is often difficult for owners to spot the signs of PPID as they frequently associate them with the ageing process. However, PPID is now the fifth most commonly diagnosed disease in horses in the UK3.
"We are therefore encouraging veterinary surgeons to routinely test horses over 15 years of age or those that are displaying signs of PPID with an ACTH test."
The 'Talk About Laminitis' disease awareness initiative runs from June until the end of October and aims to raise awareness of the underlying hormonal causes of laminitis – PPID and Equine Metabolic Syndrome (EMS). As part of the scheme, the laboratory fees for the blood test which detects PPID (the basal ACTH test) are free.
Redwings’ head of veterinary and care, senior veterinary surgeon Nicky Jarvis, said: "Any initiative that decreases the incidence of laminitis developing in an older equine is invaluable. Laminitis is an extremely distressing condition for both the horse and the owner and the long-term consequences can be devastating. Knowing the underlying cause is a huge help in tackling the disease and we would encourage anyone to take advantage of this offer and get their veteran checked out."
For further information about 'Talk About Laminitis', visit www.talkaboutlaminitis.co.uk or contact your local Boehringer Ingelheim account manager.